NWL
28
4
CSX
47
3
BK
32
7
TRV
53
4
GOOG
48
8
LUV
42
15
SYF
29
7
KEY
15
5
GME
35
2
SIG
69
2
L
46
3
MA
53
3
SPG
27
2
KMI
61
4
CMS
54
-7
XEL
62
-5
HP
55
7
RL
50
5
EQT
48
4
BAC
35
6
NWL
28
4
CSX
47
3
BK
32
7
TRV
53
4
GOOG
48
8
LUV
42
15
SYF
29
7
KEY
15
5
GME
35
2
SIG
69
2
L
46
3
MA
53
3
SPG
27
2
KMI
61
4
CMS
54
-7
XEL
62
-5
HP
55
7
RL
50
5
EQT
48
4
BAC
35
6
Financhill
Back

TransMedics Group 10K Form

Buy
60

TMDX
TransMedics Group

Last Price:
75.53
Seasonality Move:
-2.99%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TMDX News And Ratings

See the #1 stock for the next 7 days that we like better than TMDX

TMDX Financial Statistics

Sales & Book Value

Annual Sales: $93.46M
Cash Flow: $-6.8M
Price / Cash Flow: 0
Annual Sales: $5.83
Price / Book: 12.99

Profitability

EPS (TTM): -1.25000
Net Income (TTM): $-36.23M
Gross Margin: $65.27M
Return on Equity: -32.71%
Return on Assets: -19.52%

TransMedics Group Earnings Forecast

Key TransMedics Group Financial Ratios

  • The Gross Profit Margin over the past 7 years for TMDX is 69.84%.
  • The Selling, General & Administrative Expenses for TMDX have been equal to 74.79% of Gross Profit Margin.
  • The Research & Development expenses have been 28.69% of Revenue.
  • The Interest Expense is -10.30% of Operating Income.
  • The Net Earning history of TMDX is -38.77% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 4 years.

TransMedics Group Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical Devices
Sector: Healthcare
Current Symbol: TMDX
CUSIP: 89377M
Website: transmedics.com

Debt

Debt-to-Equity Ratio: 0.31
Current Ratio: 10.66
Quick Ratio: 9.67

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

TMDX Technical Analysis vs Fundamental Analysis

Buy
60
TransMedics Group (TMDX) is a Buy

Is TransMedics Group a Buy or a Sell?

  • TransMedics Group stock is rated a Buy
    The current TransMedics Group [TMDX] share price is $75.59. The Score for TMDX is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.